Fig. 6
From: Tyrosine kinase inhibitors relax pulmonary arteries in human and murine precision-cut lung slices
Involvement of K+-channels and cAMP/cGMP to the vasorelaxant effect of nilotinib. a PA (100 nM ET-1): (●) nilotinib (n = 6); (
) 10 μM glibenclamide / nilotinib (n = 4)(⃝) 10 μM glibenclamide (n = 6); b PA (100 nM ET-1): (●) nilotinib (n = 6); (
) 100 nM iberiotoxin / nilotinib (n = 5) (⃝) 100 nM iberiotoxin (n = 6); c PA (100 nM ET-1): (●) nilotinib (n = 6); (
) 5 mM 4-AP / nilotinib (n = 6)(⃝) 5 mM 4-AP (n = 6). d Effect of nilotinib on cAMP. e Effect of nilotinib on cGMP. a-c EC50 values were calculated using the standard 4-paramter logistic non-linear regression model. If EC50 values were not calculable (controls with K+-channel inhibitors), a LMM was applied. d, e Statistics were performed by the Mann-Whitney U test. P < 0.05 are considered as significant: * p < 0.05, ** p < 0.01 and *** p < 0.001